16 hrs ago
The Best Blood Cancer Drug Launch Ever?
Last night, Pharmacyclics reported a quarterly loss of 26 cents per share, far higher than the 11 cents forecast by Wall Street analysts, as it paid $50 million to Johnson & Johnson to help cover the launch of its cancer drug Imbruvica, which J&J co-markets.
22 hrs ago
Law Firm Newswire
First Two DePuy Pinnacle Cases Trial-Ready by September 1, Notes Rottenstein Law Group LLP
Rockville Centre, NY August 1, 2014 - The Rottenstein Law Group LLP is currently representing plaintiffs with claims stemming from injuries allegedly caused by metal-on-metal DePuy Pinnacle hip replacement devices .
Thu Jul 31, 2014
J&J Withdraws Power Morcellators
Johnson & Johnson is withdrawing its laparoscopic power morcellators from hospitals amid concerns that the devices may potentially spread undetected uterine sarcoma during fibroid removal and hysterectomy, the Wall Street Journal reports.
Why Johnson & Johnson (JNJ) Stock Is Lower Today
The company plans to tell customers world-wide in a letter today to return the devices known as laparoscopic power morcellators, the Journal said, STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months.
National Public Radio
Senate Antitrust Panel Eyes Contact Lens Pricing Policies
Under "UPP," or universal pricing policies, manufacturers like Johnson & Johnson tell retailers they can't sell their contact lens below a certain price.
Wed Jul 30, 2014
The Washington Post
J&J Pulls From Market Hysterectomy Device Tied to Cancer Spread
Johnson & Johnson is pulling from the global market a device used during hysterectomies and other uterine procedures after reports that it may spread and accelerate the growth of undetected cancer inside women.
The News Tribune
J&J withdraws fibroid treatment device from market
In April, J&J suspended sales of the devices, known as laparoscopic power morcellators, after the Food and Drug Administration discouraged doctors from using them.
Mon Jul 28, 2014
One Put, One Call Option To Know About for Johnson & Johnson
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Johnson & Johnson .
Thu Jul 24, 2014
Johnson & Johnson partners with Organovo to consider 3D-printing living tissue
The partnership centers around using bioprinted tissue to discover new drugs. The announcement comes ahead of Organovo's commercial launch later this year.
The New Zealand Herald
What's best for baby?
Sharon Dowling, research and development manager for leading company Johnson & Johnson , shares her advice.
Wed Jul 23, 2014
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2014
We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people.
Tue Jul 22, 2014
The Motley Fool
3 Quotes From Johnson & Johnson's Conference Call You Need to Read
Here are three quotes from the call and some commentary about why they're so important.
Mon Jul 21, 2014
Johnson & Johnson (JNJ) Declares 70c Quarterly Dividend
The quarterly dividend is in line with the company's previous. The dividend is payable on Sept.
Wed Jul 16, 2014
Johnson & Johnson Given "Neutral" Rating at Zacks
's stock had its "neutral" rating reaffirmed by Zacks in a note issued to investors on Wednesday.
Johnson & Johnson Earnings: New Blockbuster Drug Olysio Lifts Sales But May Face Competition Soon
Johnson & Johnson recently released its second quarter results. While the company beat consensus estimates, its stock fell slightly due to a weaker-than-expected outlook for the second half of 2014.
J&J's Strong 2Q Led by Pharmaceuticals
Johnson & Johnson reported strong second-quarter results that exceeded both our and consensus expectations largely because of stronger-than-expected pharmaceutical sales.
Americans stock up on Tylenol, baby products
Americans have also been stocking up on anti-smoking aids, baby products, Aveeno skin care products and even Listerine mouthwash, according to the company.
Tue Jul 15, 2014
Johnson & Johnson Beats on EPS but Sags on a Technical Basis
The large-cap pharmaceutical company also beat on revenue and raised full-year guidance.
HAPPI/Household & PP Industry
Q2 Sales Rise at J&J
Johnson & Johnson posted a 9.1% increase in sales of $19.5 billion for the second quarter of 2014.
J&J beats forecasts, helped by new hepatitis C drug
Johnson & Johnson reported sharply better-than-expected quarterly revenue and earnings, fueled by strong sales of newer prescription drugs, including its Olysio treatment for hepatitis C. The diversified healthcare company on Tuesday said it earned $4.33 billion, or $1.51 per share, in the second quarter.